Alkermes plc (ALKS) News
Follow Alkermes plc (ALKS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Alkermes Price Target Announced at $50.00/Share by Goldman Sachs
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 12:03 PM UTC
L
Needham reiterates Buy on Alkermes, $62 price target
Needham reiterated a Buy rating on Alkermes and set a $62.00 price target, implying 42.9% upside versus the Sep 18 close of $43.39.
EQUITY | Sep 21, 2026, 02:01 PM UTC
M
Alkermes reports positive Phase 1b topline in adult ADHD
Alkermes said its Phase 1b proof-of-concept for ALKS 7290, an oral OX2R agonist, showed dose-dependent improvements on exploratory ADHD scales after 14 days and a favorable safety profile. A Phase 2 adult ADHD study is e
EQUITY | Sep 21, 2026, 11:00 AM UTC
M
Alkermes reports positive Phase 1b topline results for ALKS 7290 in adult ADHD
Alkermes said it has positive topline results from a Phase 1 proof-of-concept study of ALKS 7290, an investigational orexin 2 receptor (OX2R) agonist, in adults with attention-deficit hyperactivity disorder (ADHD).
EARNINGS | Sep 21, 2026, 11:00 AM UTC
L
Alkermes to accept applications for 9th Pathways Research Awards from Sept. 11, 2026
Alkermes plc (Nasdaq: ALKS) said it will begin accepting applications for its Alkermes Pathways Research Awards program on Friday, Sept. 11, 2026.
EQUITY | Sep 10, 2026, 11:00 AM UTC
H
among early movers from the earnings calendar this morning gainers IQV +10.2%, KNSA +9.4%, ITRI +7.9%, SHW +7.5%, PII +5.8%, CTS +5.0%, XPRO
among early movers from the earnings calendar this morning gainers IQV +10.2%, KNSA +9.4%, ITRI +7.9%, SHW +7.5%, PII +5.8%, CTS +5.0%, XPRO +3.8%, KO +3.8%, ABG +3.7%, AXTA +3.5%, OSK +3.3%, RGEN +2.6%, AWI +2.3%, ITW +
EARNINGS | Jul 28, 2026, 12:58 PM UTC
L
ALKS -5% premarket after results
ALKS -5% premarket after results
EQUITY | Jul 28, 2026, 12:47 PM UTC
L
ALKS Reiterate Overweight, raise PT to $65 (from $43) – making a case for further value creation @ Piper
ALKS Reiterate Overweight, raise PT to $65 (from $43) – making a case for further value creation @ Piper
EQUITY | Jul 28, 2026, 12:26 PM UTC
L
Alkermes reports Q2 revenue $496.0M, consensus $457.36M
Reports GAAP EPS 0c vs....
EQUITY | Jul 28, 2026, 11:25 AM UTC
L
Alkermes reaffirms FY26 revenue view $1.73B-$1.84B, consensus $1.81B
Sees adjusted EBITDA...
EQUITY | Jul 28, 2026, 11:23 AM UTC
L
Alkermes reports Q2 EPS 0c, consensus 29c
Reports Q2 revenue $496M,...
EARNINGS | Jul 28, 2026, 11:19 AM UTC
L
Alkermes Affirms FY2026 Sales Guidance of $1.730B-$1.840B vs $1.812B Est
Alkermes (NASDAQ: ALKS ) affirms FY2026 sales outlook from $1.730 billion-$1.840 billion to $1.730 billion-$1.840 billion vs $1.812 billion estimate.
EARNINGS | Jul 28, 2026, 11:07 AM UTC
H
earnings calendar: • earnings before the open: ab abg alks amt awi axta ba cac carr cbu CMS cnc cts curb cvlt dino dte ecl fele fmx glw GSK
earnings calendar: • earnings before the open: ab abg alks amt awi axta ba cac carr cbu CMS cnc cts curb cvlt dino dte ecl fele fmx glw GSK hlt hri hubb iny inio iqv itri itw ivz jblu ko naut osk pcar phg pii pny pypl rc
EQUITY | Jul 28, 2026, 10:47 AM UTC
L
ALKS Reiterate Buy and $63 PT (from $45) ahead of Q4 readouts @ Stifel
ALKS Reiterate Buy and $63 PT (from $45) ahead of Q4 readouts @ Stifel
EQUITY | Jul 20, 2026, 11:26 AM UTC
L
American Express, Biogen upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: JPMorgan upgraded American Express
EQUITY | Jul 13, 2026, 01:43 PM UTC
L
Mizuho Maintains Outperform on Alkermes, Raises Price Target to $65
Mizuho analyst Uy Ear maintains Alkermes (NASDAQ: ALKS ) with a Outperform and raises the price target from $53 to $65.
EQUITY | Jul 02, 2026, 11:27 AM UTC
M
ALKS Hits Highs
ALKS reaches new highs
EQUITY | Jun 25, 2026, 02:43 PM UTC
M
ALKS: Needham Raises PT
Needham maintains buy rating on Alkermes and raises price target to $61
EQUITY | Jun 24, 2026, 11:12 AM UTC